Abstract: A composition contains one or more aromatic amino acids and optionally vitamin B6. The composition may be an oral nutritional composition, for example a nutritional supplement, an oral nutritional supplement, a food product, a food for special medical purpose (FSMP). The composition can be in a form of a powder, a powdered stick, a capsule or a solution. The composition can be administered to an individual in need thereof orally or intravenously for preventing and/or treating sarcopenia, a loss of and/or improving skeletal muscle mass, lean muscle mass, skeletal muscle strength and/or skeletal muscle function.

Abstract: Compositions consist essentially of trigonelline or consist of trigonelline. The compositions can be used in food or beverage applications, pharmaceutical formulations, or as a dietary supplement. The compositions can be administered to a mammal to treat or prevent a mitochondria-related disease or a condition associated with altered mitochondrial function in an individual in need thereof or at risk thereof. The mitochondria-related disease or condition is selected from the group consisting of deleterious effects of aging, stress (e.g.

Abstract: A combination of caffeine and at least one of oleuropein or metabolite thereof for use by oral administration to an individual in an amount effective to achieve at least one result that is (i) improved mitochondrial calcium uptake in muscle cells, (ii) improved utilization of calcium in muscle cells, (iii) increased mitochondrial energy in muscle cells, (iv) improvement in at least one of muscle functionality, muscle performance, or muscle strength, (v) decreased muscle fatigue, (vi) increased mobility, and/or (vii) treatment of a muscle disorder linked to calcium depletion or deficiency. The individual can be at least one of an aging subject; an elderly subject; a subject with muscle fatigue or muscle weakness; a subject with impaired mobility; a frail subject; a pre-frail subject; a sarcopenic subject; a subject recovering from pre-frailty, frailty, sarcopenia or impaired mobility; a subject undergoing physical rehabilitation; a sportsman; or a pet.

Abstract: Composition comprising a combination of oleuropein or metabolite thereof and fisetin or derivative thereof are provided. The composition may be an oral nutritional composition, for example a nutritional supplement, an oral nutritional supplement, a food product, a food for special medical purpose (FSMP). The composition can be administered to an individual in need thereof for improving a physiological state linked to metabolic fatigue in one or more cells, (ii) increasing mitochondrial energy and mitochondrial calcium uptake in one or more cells, and (iii) increasing antioxidant capacity, reducing oxidative stress and/or enhancing mitochondrial function, (iv) treating or preventing a calcium deficiency/depletion disorder in an individual. Additionally or alternatively, the method can treat or prevent a mitochondria-related disease or a condition associated with altered mitochondrial function in an individual in need thereof or at risk thereof.

Abstract: Composition comprising a combination of fisetin or derivative thereof and quercetin or derivative thereof are provided. The composition may be an oral nutritional composition, for example a nutritional supplement, an oral nutritional supplement, a food product, a food for special medical purpose (FSMP). The composition can be administered to an individual in need thereof for improving a physiological state linked to metabolic fatigue in one or more cells, (ii) increasing mitochondrial energy and mitochondrial calcium uptake in one or more cells, and (iii) increasing antioxidant capacity, reducing oxidative stress and/or enhancing mitochondrial function, (iv) treating or preventing a calcium deficiency/depletion disorder in an individual. Additionally or alternatively, the method can treat or prevent a mitochondria-related disease or a condition associated with altered mitochondrial function in an individual in need thereof or at risk thereof.

Abstract: The present invention relates to use of a composition comprising an effective amount of a combination of fisetin and/or derivative thereof and quercetin and/or derivative for maintenance of joint health or prevention or treatment of joint disorders in an individual. In particular, the invention relates to a composition comprising an effective amount of a combination of fisetin and/or derivative thereof and quercetin and/or derivative for use to prevent or treat cartilage degeneration in an individual.

Abstract: A combination of creatine and at least one of oleuropein or metabolite thereof for use by oral administration to an individual in an amount effective to achieve at least one result that is (i) improved mitochondrial calcium uptake in muscle cells. (ii) improved utilization of calcium in muscle cells, (iii) increased mitochondrial energy in muscle cells, (iv) improvement in at least one of muscle functionality, muscle performance, lean muscle mass or muscle strength, (v) decreased muscle fatigue, (vi) increased mobility, and/or (vii) treatment of a muscle disorder linked to calcium depletion or deficiency. The individual can be at least one of an aging subject; an elderly subject; a subject with muscle fatigue or muscle weakness; a subject with impaired mobility; a frail subject; a pre-frail subject; a sarcopenic subject; a subject recovering from pre-frailty, frailty, sarcopenia or impaired mobility; a subject undergoing physical rehabilitation; a sportsman; or a pet.

Abstract: The present invention relates to use of a composition comprising an effective amount of a combination of oleuropein and/or metabolite thereof and fisetin and/or derivative for maintenance of joint health or prevention or treatment of joint disorders in an individual. In particular, the invention relates to a composition comprising an effective amount of a combination of oleuropein and/or metabolite thereof and fisetin and/or derivative for use to prevent or treat cartilage degeneration in an individual.

Abstract: A method of preventing or treating muscle fatigue from exercise and/or for resistance to muscle fatigue from exercise, the method including orally administering at least one of oleuropein or metabolite thereof to an individual before, during and/or after the exercise. A unit dosage form contains at least one of oleuropein or metabolite thereof in an amount effective for administration of the unit dosage form before, during and/or after exercise to thereby prevent or treat muscle fatigue from the exercise and/or for resistance to muscle fatigue from exercise. A method of making a composition for preventing or treating muscle fatigue from exercise and/or for resistance to muscle fatigue from exercise, the method including adding an effective amount of at least one of oleuropein or metabolite thereof to at least one ingredient selected from the group consisting of protein, carbohydrate, and fat.

Abstract: Composition containing Nicotinamide and vitamin B6 are provided. The composition may be an oral nutritional composition, for example a nutritional supplement, an oral nutritional supplement, a food product, a food for special medical purpose (FSMP). The composition can be administered to an individual in need thereof for treating muscle injury, and/or promoting muscle repair, improving skeletal muscle regeneration, maintaining or increasing skeletal muscle function and/or skeletal muscle mass in an individual with muscle injury.

Abstract: A method of improving and/or enhancing at least one of bone mineralization, bone strength, bone mass, and bone mineral density in an individual in need thereof, the method comprising administering to the individual a composition comprising one or more anabolic amino acids, and the composition further comprising one or more autophagy-inducing compounds. In one embodiment, the one or more autophagy-inducing compounds are selected from the group consisting of thymol, carvacrol, spermidine, urolithin (e.g., Urolithin A, B or D), rapamycin, Torin1, valproic acid, polyphenols (e.g., resveratrol), caffeine, metformin, 5? AMP-activated protein kinase (AMPK) activators, L-type calcium channel inhibitors, ketones (e.g. beta-hydroxybutyrate, ketone salts, or ketone ester derivatives), 4,4?-dimethoxychalcone and mixtures thereof.

Abstract: A method of potentiating musculoskeletal effect of one or more anabolic amino acids in an individual in need thereof can include administering to the individual in need thereof a composition containing the one or more anabolic amino acids, the composition also containing one or more autophagy-inducing amino acids in a total amount effective for the composition to be at least neutral regarding autophagy. In another aspect, a method of overcoming one or more negative effects of one or more anabolic amino acids by preventing degenerative processes related to loss of autophagy can include administering to an individual in need thereof a composition containing the one or more anabolic amino acids, the composition further containing the one or more autophagy-inducing amino acids in a total amount effective for the composition to be at least neutral regarding autophagy.

Abstract: A compound having the formula (1), (2), (3), or (4), or combinations thereof, for use to maintain or increase muscle function and/or mass in a subject, and/or prevent or reduce muscle wasting in a subject, wherein R1, R2, R3, R4, R5 and R6 are independently, a long chain fatty acid having between 16 and 20 carbons.

Abstract: A compound having the formula or combinations thereof, for use to maintain or increase muscle function and/or mass in a subject, and/or prevent or reduce muscle wasting in a subject, wherein R1, R2, R3, R4, R5 and R6 are independently, a long chain fatty acid having between 16 and 20 carbons.

Abstract: The present disclosure generally relates to methods and compositions comprising urolithin that treat or prevent a disease or condition associated with muscle decline and/or a kidney dysfunction. Moreover, methods and compositions comprising urolithin for increasing the urinary creatinine and/or for decreasing the albumin/creatinine ratio and/or for increasing the albumin reabsorption. In addition, methods and compositions comprising urolithin to improve the lean mass of a muscle and/or to improve the muscle fiber size and/or to improve the level of at least one amino acid are disclosed.

Abstract: Compositions and methods using a combination of oleuropein and Magnesium Composition comprising a combination of oleuropein or metabolite thereof and Magnesium thereof are provided. The composition may be an oral nutritional composition, for example a nutritional supplement, an oral nutritional supplement, a food product, a food for special medical purpose (FSMP). The composition can be administered to an individual in need thereof for improving a physiological state linked to metabolic fatigue in one or more cells, (ii) increasing mitochondrial energy and mitochondrial calcium uptake in one or more cells, and (iii) increasing antioxidant capacity, reducing oxidative stress and/or enhancing mitochondrial function, (iv) treating or preventing a calcium deficiency/depletion disorder in an individual. Additionally, or alternatively, the method can treat or prevent a mitochondria-related disease or a condition associated with altered mitochondrial function in an individual in need thereof or at risk thereof.

Abstract: Composition comprising a combination of oleuropein or metabolite thereof and Vitamin B6 thereof are provided. The composition may be an oral nutritional composition, for example a nutritional supplement, an oral nutritional supplement, an RTD, an RTD concentrate, a food product, a food for special medical purpose (FSMP). The composition can be administered to an individual in need thereof for improving a physiological state linked to metabolic fatigue in one or more cells, (ii) increasing mitochondrial energy and mitochondrial calcium uptake in one or more cells, and (iii) increasing antioxidant capacity, reducing oxidative stress and/or enhancing mitochondrial function, (iv) treating or preventing a calcium deficiency/depletion disorder in an individual. Additionally or alternatively, the method can treat or prevent a mitochondria-related disease or a condition associated with altered mitochondrial function in an individual in need thereof or at risk thereof.

Abstract: Compositions contain an autophagy inducer and are administered before, during and/or after an intermittent fasting (IF) diet, preferably a time-restricted feeding (TRF) regimen or an alternate day fasting (ADF) regimen. For example, enhanced intermittent fasting provided by the compositions and methods disclosed herein can include improvement of at least one of longevity, cardiometabolic health, body composition (e.g., fat mass reduction), cellular ageing (e.g., reduction in inflammation markers), cellular renewal, ketosis, weight loss, glycemic control, blood pressure, satiety, or treatment of gastroesophageal reflux disease (GERD). Another aspect is a method of treating or preventing an inflammatory condition, such as rheumatoid arthritis and/or osteoarthritis, by administering an autophagy inducer before, during and/or after an intermittent fasting (IF) diet.

Abstract: The present invention relates to use of a composition comprising an effective amount of a combination of oleuropein and/or metabolite thereof and quercetin and/or derivative for maintenance of joint health or prevention or treatment of joint disorders in an individual. In particular, the invention relates to a composition comprising an effective amount of a combination of oleuropein and/or metabolite thereof and quercetin and/or derivative for use to prevent or treat cartilage degeneration in an individual.

Abstract: Composition comprising a combination of oleuropein or metabolite thereof and nicotinamide riboside thereof are provided. The composition may be an oral nutritional composition, for example a nutritional supplement, an oral nutritional supplement, a food product, a food for special medical purpose (FSMP). The composition can be administered to an individual in need thereof for (i) improving a physiological state or disorder related to NAD deficiency/restriction in one or more cells, (ii) improving a physiological state linked to metabolic fatigue in one or more cells, (iii) increasing mitochondrial energy and mitochondrial calcium uptake in one or more cells, and (iv) increasing antioxidant capacity, reducing oxidative stress and/or enhancing mitochondrial function, (v) treating or preventing a NAD deficiency/depletion disorder in an individual, (vi) improving healthspan.